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Caused by infection with Plasmodium spp. parasites, malaria 
continues to be an enormous economic and global health bur-
den.1 Malaria control worldwide has been hampered by wide-
spread parasite resistance to all commonly used antimalarial 
therapies, including delayed clearance by front-line artemisinin-
based agents. Plasmodium spp. and other apicomplexan parasites 
possess an unusual plastid organelle, the apicoplast. As a result, 
malaria parasites deploy an essential plastidial pathway for iso-
prenoid biosynthesis, the methylerythritol phosphate (MEP) 
pathway, which is vital for parasite growth but not shared by the 
human host. The phosphonate antibiotic fosmidomycin (FSM) 
is a competitive inhibitor of the first dedicated step of the MEP 
pathway, catalyzed by deoxyxylulose reductoisomerase. 
Although poor drug-like characteristics of FSM have limited 
its development as a clinical antimalarial, its highly specific 
mechanism-of-action has been invaluable as a chemical tool to 
probe MEP pathway regulation and biology.
Guggisberg et al2 used FSM resistance as a strategy to probe 
metabolic regulatory networks in asexual Plasmodium falciparum 
parasites. Wild-type parasites were subjected to FSM selective 
pressure, and whole-genome sequencing was performed on the 
drug-resistant parasites that emerged. The researchers focused on a 
particular nucleotide polymorphism in PF3D7_1226300, which 
encodes a haloacid dehalogenase (HAD) protein family member, 
termed HAD2. Fosmidomycin-resistant had2 parasites were found 
to have a dramatic dysregulation of central carbon metabolism and 
downstream MEP pathway metabolites, leading to poor asexual 
growth and FSM resistance. In the absence of FSM pressure, had2 
parasites acquired additional suppressive mutations in the glyco-
lytic enzyme phosphofructokinase (PFK9). Reduced PFK9 func-
tion restored growth and FSM sensitivity to parasites lacking 
HAD2. This work reveals an important and unexpected mecha-
nism of plasticity in a core glycolytic process in P falciparum.
In addition, this study marks a second example linking a 
HAD protein family member to cellular metabolic homeosta-
sis in malaria parasites. Loss of the HAD protein family mem-
ber HAD1, a close homolog of HAD2, also results in FSM 
resistance in P falciparum, accompanied by remarkable changes 
in MEP pathway metabolites.3 Together, these results suggest 
a common, conserved, and vital role for HAD superfamily 
members in metabolic regulation. Bolstering support for this 
model of HAD-mediated metabolic control, genetic disrup-
tion of a third HAD protein family member, the putative phos-
phoglycolate phosphatase (PGP; PF3D7_0715000) of P 
falciparum, also appears to lead to metabolic dysregulation. In 
this case, loss of HAD function results in increased sensitivity 
to FSM, rather than resistance.4 Additional compelling studies 
suggest that this newly identified role of HAD proteins in 
regulating metabolism is not unique to malaria parasites, as 
Wang et al find that multiple phosphatases, including several 
HAD proteins, modulate production of isoprenoids in 
Escherichia coli.5
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HAD proteins are characterized by a Rossmannoid fold and 
4 highly conserved sequence motifs in their catalytic core 
domain, in addition to the presence of a hinged cap domain. 
This cap domain provides substrate specificity through close 
interactions with substrates. The characteristic organization of 
this substrate-defining cap domain within the gene sequence is 
the basis for dividing HAD superfamily enzymes into 3 dis-
tinct subfamilies (subfamily I, II, and III, respectively; Figure 
1).6 Although the namesake of this large superfamily of pro-
teins (>600 000 members of InterPro IPR023214) is a bacte-
rial HAD, most HAD enzymes instead catalyze 
phosphate-transferring reactions. Most (nearly 70%) of the 
HAD proteins are phosphatases, with many more performing 
phosphomutase, phosphonatase, or phosphotransferase activi-
ties.7 Biochemical analyses of HAD proteins in vitro have 
demonstrated that they dephosphorylate a wide range of phos-
phosubstrates, including nucleotide phosphates, sugar phos-
phates, phosphorylated cofactors, and occasionally 
phosphoproteins.8,9 Moreover, these studies reveal that many 
HAD proteins have wide and promiscuous substrate profiles, 
such that a number of HAD proteins are annotated as “non-
specific” cellular phosphatases. By contrast, other HAD pro-
teins have much more narrow substrate specificity profiles. 
Importantly, much of the substrate profiling of HAD enzymes 
relies on in vitro phosphatase assays, and few attempts have 
been made to validate these substrates in a cellular context, 
where substrate availability may determine which substrates 
are most commonly used. It is difficult, therefore, to distinguish 
between the broad in vitro substrate profiles of HAD proteins 
and their potentially narrower roles in a biological context.
In the P falciparum genome, there are roughly 23 genes con-
taining HAD superfamily domains (IPR023214). Based on 
sequence homology, many of these have been annotated as P-type 
ATPases. Several others contain FCP1-like domains, homolo-
gous to the essential protein serine phosphatase in yeast, FCP1. P 
falciparum possesses a single HAD subfamily I member, as well as 
a single subfamily III member. However, the HAD subfamily 
II is expanded in the P falciparum genome (Figure 1). Notably, the 
3 HAD superfamily protein members that have been 
implicated in metabolic regulation and FSM sensitivity of P 
Figure 1. Phylogenetic tree of HAD superfamily (IPR023214) proteins from P falciparum. Established protein names are given in parentheses, where 
applicable. HAD1, HAD2, and PGP all fall within subfamily II of HAD proteins, and cluster near each other phylogenetically. Proteins are color-coordinated 
by the presence of InterPro domains as follows: HAD subfamily I (IPR006439), HAD subfamily II (IPR006379 and IPR006357), HAD subfamily III 
(IPR006549), P-type ATPase (IPR006539 and IPR008250), and FCP1 homology domain (IPR004274). Phylogenetic analysis was performed by 
ClustalW2 from EMBL-EBI, using the neighbor-joining method with distance correction. HAD indicates haloacid dehalogenase; PGP, phosphoglycolate 
phosphatase.
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falciparum—HAD1, HAD2, and PGP—all fall within subfamily 
II of HAD superfamily proteins and cluster together phyloge-
netically (Figure 1). The other genes clustered within this group 
include 3 additional subfamily II members [annotated as a phos-
phomannomutase (PF3D7_1017400) and 2 hydrolases of 
unknown function (PF3D7_1226100 and PF3D7_1118400)], as 
well as guanylyl cyclase β (PF3D7_1360500). An important 
question for future investigation is whether the biological func-
tions of HAD1, HAD2, and PGP in metabolic regulation and 
drug-sensitivity are more broadly applicable to other HAD pro-
teins, or are limited to this subset of closely related HAD1-like 
homologs.
Although increasing evidence indicates that HAD protein 
family members, and specifically HAD subfamily II members, 
modulate metabolic homeostasis in P falciparum, the cellular 
mechanism by which HAD enzymes control metabolism 
remains yet undefined. We propose 2 hypothetical models of 
how HAD protein family members may regulate cellular 
metabolite levels (Figure 2). In the first model, HAD proteins 
regulate metabolism directly by enzymatically converting sub-
strates that would otherwise directly feed into biosynthetic 
pathways (Figure 2A). Thus, loss of HAD activity causes a 
build-up of phosphosubstrate levels, leading to increased 
availability of these compounds for downstream metabolic 
reactions. To date, however, most of the genetic changes 
described in HADs not only reduce catalytic activity but also 
lead to substantially reduction of overall HAD protein levels. 
Therefore, the metabolic changes in had mutants may be due to 
the loss of HAD activity or, alternatively, due in part to some 
non-catalytic “moonlighting” function of HADs. In this alter-
native model of HAD-mediated metabolic regulation, enzy-
matic activity serves as a molecular switch between “active” and 
“inactive” conformational states (Figure 2B). Following the 
paradigm established by small GTPases (such as Ras and Rab 
homologs),10 the conformational change in a given HAD 
might modulate localization or protein-protein interactions to 
mediate a regulatory effect. In support of this alternative model, 
structural studies of substrate-bound HAD1 by Park et  al11 
find that HAD1 undergoes a large conformational change 
(from an “open” to “closed” conformation) during cap domain 
closure on substrate binding.
HAD proteins make up an enormous superfamily of 
enzymes that are involved in a wide range of metabolic path-
ways. In addition to the annotated biochemical activities of 
many HAD proteins across biology, a novel role for HAD pro-
teins has emerged through studying malaria parasites: control 
Figure 2. Mechanistic models of HAD-mediated metabolic regulation. (A) In Model 1, HAD proteins catalyze the bulk flow of metabolites from one state to 
another. (B) In Model 2, substrate binding and hydrolyses instead induce conformational changes that dictate the regulatory functions of HAD proteins, 
perhaps by mediating localization or protein-protein interactions. HAD indicates haloacid dehalogenase.
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of metabolic homeostasis and drug sensitivity. Parasites that 
lack certain HAD enzymes can be either sensitized to or resist-
ant to FSM, at the expense of intra-erythrocytic growth rates, 
and exhibit global changes to their core metabolism. 
Understanding the underlying mechanisms by which malaria 
parasites control essential metabolism may guide development 
of future therapeutic strategies to combat malaria. In addition, 
studies of Plasmodium HADs are likely to reveal paradigms 
that may apply to the many thousands of HAD proteins across 
the domains of life, whose cellular functions are currently 
unknown.
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